Citadel Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $536K | Buy |
462,340
+391,282
| +551% | +$454K | ﹤0.01% | 3984 |
|
|
2025
Q1 | $113K | Sell |
71,058
-3,145,669
| -98% | -$5M | ﹤0.01% | 5109 |
|
|
2024
Q4 | $9.75M | Buy |
3,216,727
+499,206
| +18% | +$1.51M | ﹤0.01% | 1340 |
|
|
2024
Q3 | $10M | Sell |
2,717,521
-1,785,392
| -40% | -$6.57M | ﹤0.01% | 1259 |
|
|
2024
Q2 | $18.4M | Buy |
4,502,913
+650,484
| +17% | +$2.66M | ﹤0.01% | 905 |
|
|
2024
Q1 | $60.7M | Buy |
3,852,429
+170,647
| +5% | +$2.69M | 0.01% | 409 |
|
|
2023
Q4 | $55.8M | Buy |
3,681,782
+1,526,431
| +71% | +$23.1M | 0.01% | 426 |
|
|
2023
Q3 | $43.2M | Buy |
2,155,351
+26,055
| +1% | +$523K | 0.01% | 482 |
|
|
2023
Q2 | $60.1M | Buy |
2,129,296
+799,303
| +60% | +$22.5M | 0.01% | 365 |
|
|
2023
Q1 | $22.9M | Buy |
1,329,993
+692,273
| +109% | +$11.9M | 0.01% | 791 |
|
|
2022
Q4 | $12.8M | Buy |
637,720
+84,919
| +15% | +$1.71M | ﹤0.01% | 1126 |
|
|
2022
Q3 | $12M | Sell |
552,801
-209,894
| -28% | -$4.55M | ﹤0.01% | 1138 |
|
|
2022
Q2 | $21.4M | Buy |
762,695
+251,670
| +49% | +$7.07M | 0.01% | 793 |
|
|
2022
Q1 | $23.6M | Sell |
511,025
-88,611
| -15% | -$4.09M | ﹤0.01% | 807 |
|
|
2021
Q4 | $50.4M | Sell |
599,636
-503,157
| -46% | -$42.3M | 0.01% | 479 |
|
|
2021
Q3 | $73.5M | Sell |
1,102,793
-130,187
| -11% | -$8.68M | 0.02% | 306 |
|
|
2021
Q2 | $65.6M | Buy |
1,232,980
+177,591
| +17% | +$9.45M | 0.01% | 384 |
|
|
2021
Q1 | $45.8M | Sell |
1,055,389
-448,481
| -30% | -$19.5M | 0.01% | 504 |
|
|
2020
Q4 | $78.1M | Sell |
1,503,870
-185,764
| -11% | -$9.65M | 0.02% | 282 |
|
|
2020
Q3 | $55.2M | Buy |
1,689,634
+128,947
| +8% | +$4.22M | 0.02% | 367 |
|
|
2020
Q2 | $74.9M | Buy |
+1,560,687
| New | +$74.9M | 0.03% | 245 |
|